12 June 2021: Articles
Aortic Angiosarcoma in Association with Endovascular Aneurysm Repair: Case Report and Review of the Literature
Rare disease
Kaori Takamura A* , Hiroshi Kobayashi A , Brian P. Rubin D , Shuhei Kondo B , Fuyuki Asami B , Ryuji Aoyagi B , Yoichi Ajioka DDOI: 10.12659/AJCR.931740
Am J Case Rep 2021; 22:e931740
Table 2. Clinicopathologic features of reported aortic angiosarcomas associated with aortic prostheses.
| Author/Year | Reference | Sex | Age | Surgical procedures | Site of aneurysm | Size of tumor |
|---|---|---|---|---|---|---|
| O’Connell TX, 1976 | 7 | M | 59 | AR | AA | 7 cm |
| Weinberg DS, 1980 | 8 | M | 48 | AR | TA | 7.4×1.5×2 cm |
| Fehrenbacher JW, 1981 | 9 | M | 67 | AR | AA | 6×2.4 cm |
| Peterson HS, 1989 | 10 | M | 57 | AR | TA | N.D. (a large mass) |
| Weiss WM, 1991 | 11 | M | 56 | AR | AA | 6×4×3.5 cm |
| Fyfe BS, 1994 | 12 | M | 70 | AR | TA | N.D. |
| Ben-Izhak O, 1999 | 13 | M | 71 | AR | AA | 5.5×4.5 cm |
| Okada M, 2004 | 14 | M | 50 | AR | TA | N.D. |
| Umscheid TW, 2007 | 15 | M | 50 | EVAR | AA | N.D. |
| Alexander JJ, 2007 | 16 | M | 66 | AR | AA | 1.6×0.8 cm |
| Garg N, 2012 | 17 | M | 56 | EVAR | AA | N.D. |
| Schmehl J, 2012 | 18 | M | 85 | EVAR | AA | N.D. |
| Stewart B, 2013 | 19 | M | 86 | EVAR | AA | N.D. |
| Fenton J, 2014 | 20 | M | 72 | EVAR | AA | N.D. |
| Kimura S, 2015 | 21 | M | 78 | AR | TA | 4.5×3 cm |
| Milite D, 2016 | 22 | M | 60 | EVAR | AA | 10.2 cm |
| Kamran M, 2016 | 23 | M | 69 | EVAR | AA | 3.1×2.4 cm |
| Kamran M, 2016 | 23 | M | 77 | EVAR | AA | N.D. |
| Kamran M, 2016 | 23 | F | 72 | EVAR | AA | 7.3 cm |
| Whittington EA, 2019 | 24 | M | 78 | EVAR | AA | 8.4 cm |
| Yu PC, 2019 | 25 | M | 68 | EVAR | AA | 4.2 cm |
| Natsume K, 2019 | 26 | M | 54 | AR | TA | 4.0×2.2×2 cm |
| Current case | F | 82 | EVAR | TA | 10×6.5×2 cm | |
| AR – aortic replacement with prosthetic graft; EVAR – endovascular aortic repair; AA – abdominal aorta; TA – thoracic aorta; N.D. – not described; FS – fibrosarcoma; MFH – malignant fibrous histiocytoma; AS – angiosarcoma; pMFH – pleomorphic malignant fibrous histiocytoma; eAS – epithelioid angiosarcoma; eLS – epithelioid leiomyosarcoma; SPS – spindle and pleomorphic sarcoma; +ve – positive; –ve – negative; ds – days; ws – weeks; ms – months. * Measure on the figure in original paper; ** as far as can be determined from original paper. Time from symptom onset to outcome for those not annotated. | ||||||
| Author/Year | Histology | Outcome | Time to outcome** | Autopsy | ||
| Histological diagnosis | Immunohistochemistry | |||||
| O’Connell TX, 1976 | FS | N.D. | Dead | 14.5 ms | Yes | |
| Weinberg DS, 1980 | MFH | N.D. | Perioperative death | 2 ms | Yes | |
| Fehrenbacher JW, 1981 | AS | N.D. | Dead | 7 ms | Yes | |
| Peterson HS, 1989 | MFH | N.D. | Dead | 12 ws | No | |
| Weiss WM, 1991 | AS | +ve: vimentin, Factor VIII; –ve: cytokeratins | Alive | 15 ms | – | |
| Fyfe BS, 1994 | pMFH | N.D. | Perioperative death | a few ms | Yes | |
| Ben-Izhak O, 1999 | eAS | +ve: CD31, CD34, Factor VIII, AE1/AE3, CAM5.2 | Dead | 6 ms after diagnosis | N.D. | |
| Okada M, 2004 | AS | +ve: CD31, –ve: CD34, Factor VIII | Dead | 2 ws | Yes | |
| Umscheid TW, 2007 | eAS | +ve: Factor VIII, CD34; –ve: cytokeratins | Dead | 24 ms | N.D. | |
| Alexander JJ, 2007 | IS | +ve: vimentin, pancytokeratin; –ve: CD31, CD34, Factor VIII, desmin, SMA, cytokeratin 8/18, EMA | Perioperative death | N.D. | No | |
| Garg N, 2012 | IS | +ve: CD31, Fli-1, CK7; –ve: CK20 | Dead | 6 ws after discharge | N.D. | |
| Schmehl J, 2012 | eAS | +ve: CD31, pancytokeratin, P53 (10%); –ve: CD30, EMA, CD34 | N.D. | N.D. | N.D. | |
| Stewart B, 2013 | AS | +ve: vimentin, CD31; –ve: CD34, desmin, SMA, pancytokeratin | Dead | 3 ms after last surgery | Yes | |
| Fenton J, 2014 | AS | N.D. | Dead | 1 ms after diagnosis | Yes | |
| Kimura S, 2015 | AS | N.D. | Dead | 2 ms after treatment | Yes | |
| Milite D, 2016 | eAS | +ve: vimentin, CD31, CD34, Factor VIII | Dead | 1 ms and 3 ws | N.D. | |
| Kamran M, 2016 | eAS | N.D. | Alive | 15 ms after treatment | – | |
| Kamran M, 2016 | eLS | N.D. | Dead | N.D. | N.D. | |
| Kamran M, 2016 | AS | +ve: CD31 | Alive | N.D. | – | |
| Whittington EA, 2019 | SPS | N.D. | Dead | Several ms | N.D. | |
| Yu PC, 2019 | eAS | N.D. | Alive | 2 ms after last surgery | – | |
| Natsume K, 2019 | IS | +ve: CD31, MDM2 | Dead | 5 ms and 20 ds | No | |
| Current case | eAS | +ve: vimentin, CD31, Factor VIII, ERG, pancytokeratin, CDK4; –ve: MDM2 | Dead | 8 ms | Yes | |
| AR – aortic replacement with prosthetic graft; EVAR – endovascular aortic repair; AA – abdominal aorta; TA – thoracic aorta; N.D. – not described; FS – fibrosarcoma; MFH – malignant fibrous histiocytoma; AS – angiosarcoma; pMFH – pleomorphic malignant fibrous histiocytoma; eAS – epithelioid angiosarcoma; eLS – epithelioid leiomyosarcoma; SPS – spindle and pleomorphic sarcoma; +ve – positive; –ve – negative; ds – days; ws – weeks; ms – months. * Measure on the figure in original paper; ** as far as can be determined from original paper. Time from symptom onset to outcome for those not annotated. | ||||||